SANA: Gene-modified islet cell therapy for type 1 diabetes nears phase I trial, with strong clinical and financial momentum
The company is advancing gene-modified islet cell therapy for type 1 diabetes, aiming to start a phase I trial by year-end, and is developing an in vivo CAR T platform for blood cancers. Manufacturing scalability, regulatory support, and a strong Mayo Clinic partnership are key. Cash runway extends…